CLINICAL TRIALS PROFILE FOR IPRATROPIUM BROMIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for ipratropium bromide
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00480194 ↗ | Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM) | Completed | Nycomed | 2006-12-01 | The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting. | |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for ipratropium bromide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000568 ↗ | Lung Health Study (LHS) I and III | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-09-01 | In the Lung Health Study I, to determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function. In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years. |
| NCT00000577 ↗ | Asthma Clinical Research Network (ACRN) | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1993-09-01 | This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma. |
| NCT00000577 ↗ | Asthma Clinical Research Network (ACRN) | Withdrawn | Milton S. Hershey Medical Center | Phase 3 | 1993-09-01 | This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma. |
| NCT00200967 ↗ | Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) | Completed | Asthma Clinical Research Network | Phase 3 | 2004-12-01 | The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype. |
| NCT00200967 ↗ | Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2004-12-01 | The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype. |
| NCT00200967 ↗ | Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) | Completed | Milton S. Hershey Medical Center | Phase 3 | 2004-12-01 | The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype. |
| NCT00202176 ↗ | Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD) | Completed | Queen's University | Phase 4 | 2005-07-01 | In people with mild COPD, the ability to exhale air from the lungs is partly limited because of narrowing and collapse of the airways. This results in the trapping of air within the lungs and over-distention of the lungs and chest (lung hyperinflation). Breathing at high lung volumes (hyperinflation) is an important cause of breathing discomfort (dyspnea) in people with COPD. Bronchodilators help to relax muscles in the airways or breathing tubes. Bronchodilators are often prescribed if a cough occurs with airway narrowing as this medication can reduce coughing, wheezing and shortness of breath. Bronchodilators can be taken orally, through injection or through inhalation and begin to act almost immediately but with the effect only lasting 4-6 hours. The main purpose of this study is to examine the effects of inhaled bronchodilators on breathing discomfort and exercise endurance in patients with mild COPD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ipratropium bromide
Condition Name
Clinical Trial Locations for ipratropium bromide
Trials by Country
Clinical Trial Progress for ipratropium bromide
Clinical Trial Phase
Clinical Trial Sponsors for ipratropium bromide
Sponsor Name
